Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).

Gaumann AK, Drexler HC, Lang SA, Stoeltzing O, Diermeier-Daucher S, Buchdunger E, Wood J, Bold G, Breier G.

Int J Oncol. 2014 Dec;45(6):2267-77. doi: 10.3892/ijo.2014.2683. Epub 2014 Sep 29.

2.

EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells.

Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, Jung YD.

Int J Oncol. 2013 Mar;42(3):1120-6. doi: 10.3892/ijo.2013.1775. Epub 2013 Jan 16.

PMID:
23337910
3.

STAT5b as molecular target in pancreatic cancer--inhibition of tumor growth, angiogenesis, and metastases.

Moser C, Ruemmele P, Gehmert S, Schenk H, Kreutz MP, Mycielska ME, Hackl C, Kroemer A, Schnitzbauer AA, Stoeltzing O, Schlitt HJ, Geissler EK, Lang SA.

Neoplasia. 2012 Oct;14(10):915-25.

4.

Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.

Moser C, Lang SA, Hackl C, Wagner C, Scheiffert E, Schlitt HJ, Geissler EK, Stoeltzing O.

Anticancer Res. 2012 Jul;32(7):2551-61.

PMID:
22753713
5.

Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.

Moser C, Lang SA, Hackl C, Zhang H, Lundgren K, Hong V, McKenzie A, Weber B, Park JS, Schlitt HJ, Geissler EK, Jung YD, Stoeltzing O.

Anticancer Res. 2012 Feb;32(2):427-37.

PMID:
22287729
6.

Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.

Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA.

Mol Cancer Ther. 2011 Nov;10(11):2157-67. doi: 10.1158/1535-7163.MCT-11-0312. Epub 2011 Sep 1.

7.

Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition.

Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O.

BMC Cancer. 2010 Dec 3;10:668. doi: 10.1186/1471-2407-10-668.

8.

Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?

Staufer K, Stoeltzing O.

Curr Cancer Drug Targets. 2010 Dec;10(8):890-7. Review.

PMID:
20718699
9.

Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.

Kirchner G, Kirovski G, Hebestreit A, Schölmerich J, Schlitt HJ, Stoeltzing O, Hellerbrand C.

Int J Clin Exp Med. 2010 Jun 10;3(2):169-79.

10.

Drug abuse, personality disorder, and colorectal metastases: when chemotherapy becomes an illusion and surgery cannot help any more.

Sotiropoulos GC, Tagkalos E, Molmenti EP, Gönner U, Stoeltzing O, Mildenberger P, Lang H.

Int J Colorectal Dis. 2011 Feb;26(2):261-2. doi: 10.1007/s00384-010-0978-6. Epub 2010 Jun 11. No abstract available.

PMID:
20544206
11.

Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance.

Stoeltzing O.

Cell Cycle. 2010 Jun 1;9(11):2051-2. Epub 2010 Jun 1. No abstract available.

PMID:
20505332
12.

Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells.

Lang SA, Hackl C, Moser C, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Biochim Biophys Acta. 2010 Apr;1803(4):435-42. doi: 10.1016/j.bbamcr.2010.01.009. Epub 2010 Jan 28.

13.

Effect of heat-shock protein-90 (HSP90) inhibition on human hepatocytes and on liver regeneration in experimental models.

Hackl C, Mori A, Moser C, Lang SA, Dayoub R, Weiss TS, Schlitt HJ, Geissler EK, Hellerbrand C, Stoeltzing O.

Surgery. 2010 May;147(5):704-12. doi: 10.1016/j.surg.2009.10.061. Epub 2009 Dec 16.

PMID:
20015528
14.

Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha.

Mori A, Moser C, Lang SA, Hackl C, Gottfried E, Kreutz M, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Res. 2009 Aug;7(8):1390-8. doi: 10.1158/1541-7786.MCR-08-0525. Epub 2009 Aug 11.

15.

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Moser C, Lang SA, Stoeltzing O.

Anticancer Res. 2009 Jun;29(6):2031-42. Review.

16.

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.

Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ.

Langenbecks Arch Surg. 2010 Feb;395(2):185-92. doi: 10.1007/s00423-009-0520-x. Epub 2009 Jun 9.

PMID:
19506898
17.

GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C.

Am J Pathol. 2009 Apr;174(4):1544-52. doi: 10.2353/ajpath.2009.080596. Epub 2009 Mar 12.

18.

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice.

Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O.

Hepatology. 2009 Feb;49(2):523-32. doi: 10.1002/hep.22685.

PMID:
19085954
19.

Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.

Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2008 Nov;7(11):3509-18. doi: 10.1158/1535-7163.MCT-08-0373.

20.

ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.

Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O.

BMC Cancer. 2008 Jul 23;8:206. doi: 10.1186/1471-2407-8-206.

21.

Mesenteric ischemia--outcome after surgical therapy in 83 patients.

Dahlke MH, Asshoff L, Popp FC, Feuerbach S, Lang SA, Renner P, Slowik P, Stoeltzing O, Schlitt HJ, Piso P.

Dig Surg. 2008;25(3):213-9. doi: 10.1159/000140692. Epub 2008 Jun 23.

PMID:
18577867
22.

Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.

Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK, Stoeltzing O.

Eur J Cancer. 2008 Jul;44(11):1577-86. doi: 10.1016/j.ejca.2008.04.003. Epub 2008 Apr 27.

PMID:
18445520
23.

Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.

Lang SA, Brecht I, Moser C, Obed A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O.

Langenbecks Arch Surg. 2008 May;393(3):333-41. doi: 10.1007/s00423-008-0292-8. Epub 2008 Feb 23.

PMID:
18297306
24.

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.

Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Nov;6(11):2868-78.

26.

Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) system.

Stoeltzing O, Liu W, Fan F, Wagner C, Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ, Ellis LM.

Cancer Lett. 2007 Dec 18;258(2):291-300. Epub 2007 Oct 22.

27.

The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.

Moser C, Lang SA, Stoeltzing O.

Clin Colorectal Cancer. 2007 Jul;6(8):564-71. Review.

PMID:
17681102
28.

Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.

McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, Bucana C, Ellis LM.

J Clin Invest. 2007 Aug;117(8):2114-22.

29.

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, Stoeltzing O.

Mol Cancer Ther. 2007 Mar;6(3):1123-32.

30.

Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability.

Koehl GE, Wagner F, Stoeltzing O, Lang SA, Steinbauer M, Schlitt HJ, Geissler EK.

Transplantation. 2007 Mar 15;83(5):607-14.

PMID:
17353782
31.

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.

Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O.

Int J Cancer. 2007 Apr 15;120(8):1803-10.

32.

Sirolimus promotes tolerance for donor and recipient antigens after MHC class II disparate bone marrow transplantation in rats.

Jäger MD, Liu JY, Timrott KF, Popp FC, Stoeltzing O, Lang SA, Piso P, Geissler EK, Schlitt HJ, Dahlke MH.

Exp Hematol. 2007 Jan;35(1):164-70.

PMID:
17198885
33.

No contribution of multipotent mesenchymal stromal cells to liver regeneration in a rat model of prolonged hepatic injury.

Popp FC, Slowik P, Eggenhofer E, Renner P, Lang SA, Stoeltzing O, Geissler EK, Piso P, Schlitt HJ, Dahlke MH.

Stem Cells. 2007 Mar;25(3):639-45. Epub 2006 Nov 16.

34.

Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected.

Stoeltzing O, Meric-Bernstam F, Ellis LM.

Cancer Cell. 2006 Aug;10(2):89-91. Review.

35.

Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF.

Liu W, Parikh AA, Stoeltzing O, Fan F, McCarty MF, Wey J, Hicklin DJ, Ellis LM.

Cytokine. 2005 Dec 7;32(5):206-12. Epub 2005 Nov 9.

PMID:
16289960
36.

Vascular endothelial growth factor receptors: expression and function in solid tumors.

Wey JS, Stoeltzing O, Ellis LM.

Clin Adv Hematol Oncol. 2004 Jan;2(1):37-45. Review.

PMID:
16163158
37.

Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.

Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM.

Br J Cancer. 2005 Jul 25;93(2):233-41.

39.

Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation.

Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, Ellis LM.

J Natl Cancer Inst. 2004 Jun 16;96(12):946-56.

PMID:
15199114
40.

Regulators of vascular endothelial growth factor expression in cancer.

Stoeltzing O, Ellis LM.

Cancer Treat Res. 2004;119:33-58. Review. No abstract available.

PMID:
15164872
41.

Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.

Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, Bielenberg D, Bucana CD, Klagsbrun M, Ellis LM.

Am J Pathol. 2004 Jun;164(6):2139-51.

42.

Interleukin-1beta regulates angiopoietin-1 expression in human endothelial cells.

Fan F, Stoeltzing O, Liu W, McCarty MF, Jung YD, Reinmuth N, Ellis LM.

Cancer Res. 2004 May 1;64(9):3186-90.

43.

Effects of overexpression of ephrin-B2 on tumour growth in human colorectal cancer.

Liu W, Jung YD, Ahmad SA, McCarty MF, Stoeltzing O, Reinmuth N, Fan F, Ellis LM.

Br J Cancer. 2004 Apr 19;90(8):1620-6.

44.

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.

McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM.

Br J Cancer. 2004 Feb 9;90(3):705-11.

45.

Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells.

Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M.

Cancer Res. 2004 Jan 15;64(2):631-8.

46.

Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer.

Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, Evans DB, Semenza GL, Ellis LM.

Am J Pathol. 2003 Sep;163(3):1001-11.

47.

Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma.

Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, Bucana CD, Evans DB, Ellis LM.

Cancer. 2003 Aug 15;98(4):720-9.

48.

Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.

Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD, Fan F, Ellis LM.

Ann Surg Oncol. 2003 Aug;10(7):722-33. Review.

PMID:
12900362
49.

Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.

Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD, Fan F, Takeda A, Akagi M, Bar-Eli M, Gallick GE, Ellis LM.

Cancer Res. 2003 Jul 1;63(13):3632-6.

50.

Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.

Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD, Ellis LM.

Cancer Res. 2003 Jun 15;63(12):3370-7.

Supplemental Content

Loading ...
Support Center